Hugo Peris, Spiral Therapeutics CEO
Hearing-focused biotech grabs trio of programs from Otonomy's fire sale
Otonomy may be shutting down, but the lessons learned there will live on at another biotech working on new treatments for hearing loss.
San Francisco …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
